[Evidence of alendronate treatment for osteoporosis].
Harada
Atsushi
A
Department of Restorative Medicine, National Center for Geriatrics and Gerontology.
D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use*; D000469:Alkaline Phosphatase / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024042:Collagen Type I / Q000032:analysis; D064420:Drug-Related Side Effects and Adverse Reactions; D019317:Evidence-Based Medicine; D005260:Female; D005265:Femoral Neck Fractures / Q000517:prevention & control; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000032:analysis
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; D019386:Alendronate